Gong Y H, Jiang J X, Li Z, Zhu L H, Zhang Z Z
Department of Pharmacology, Kunming Medical College.
Yao Xue Xue Bao. 1991;26(2):81-5.
Sanchinoside C1 (ginsenoside Rg1), one of the major effective components of Panax notoginseng, was reported to be effective in lowering glucose-induced hyperglycemia and synergizing the action of insulin in normal animals. The present study was aimed at investigating its effects on diabetic animals and comparing them with that of insulin. The results showed that sanchinoside C1 was able to lower plasma glucose level in alloxan-diabetic mice. The action was strengthened with repeated administration and tended to be dose-dependent; its effect lasted for more than four hours and no synergism or antagonism between sanchinoside C1 and insulin was observed. A single dose of sanchinoside C1 neither elevated plasma insulin level nor lowered hepatic cAMP level in alloxan-diabetic mice; while the uptake of [3H] glucose by isolated rat hepatocytes, oxidation of glucose and sodium succinate in liver homogenate and synthesis of liver glycogen in normal mice were increased.
三七皂苷C1（人参皂苷Rg1）是三七的主要有效成分之一，据报道其在正常动物中可有效降低葡萄糖诱导的高血糖，并协同胰岛素发挥作用。本研究旨在研究其对糖尿病动物的影响，并与胰岛素进行比较。结果表明，三七皂苷C1能够降低四氧嘧啶糖尿病小鼠的血糖水平。反复给药后作用增强，且呈剂量依赖性；其作用持续超过4小时，未观察到三七皂苷C1与胰岛素之间的协同或拮抗作用。单剂量的三七皂苷C1既不会升高四氧嘧啶糖尿病小鼠的血浆胰岛素水平，也不会降低其肝脏cAMP水平；而正常小鼠分离的大鼠肝细胞对[3H]葡萄糖的摄取、肝匀浆中葡萄糖和琥珀酸钠的氧化以及肝糖原的合成均增加。
